SecSonar.com

Immatics N.V. (IMTX)

Immatics N.V. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Immatics N.V. (IMTX) is a Biotechnology company based in DE with a market capitalization of $1.5B. Revenue declined 69.0% year-over-year and free cash flow was negative at -$201.3M. This page tracks IMTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

DE · 554 employees · IPO Dec 12, 2018

Valuation

Valuation & price

$11.14 · as of May 26, 2026 · -6.1% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$11.87$8.48$5.09Jul 25Dec 25Jul 26Jul 7, 25$5.54Jul 9, 25$5.90Jul 11, 25$5.97Jul 15, 25$5.96Jul 17, 25$6.21Jul 21, 25$5.85Jul 23, 25$6.45Jul 25, 25$6.56Jul 29, 25$6.63Jul 31, 25$6.45Aug 4, 25$6.61Aug 6, 25$6.34Aug 11, 25$6.34Aug 13, 25$6.10Aug 15, 25$6.33Aug 19, 25$5.59Aug 21, 25$5.63Aug 25, 25$5.23Aug 27, 25$5.40Aug 29, 25$5.09Sep 3, 25$5.45Sep 5, 25$6.26Sep 9, 25$5.79Sep 11, 25$5.92Sep 16, 25$6.00Sep 18, 25$6.61Sep 22, 25$6.85Sep 24, 25$7.33Sep 26, 25$7.70Sep 30, 25$8.52Oct 2, 25$8.73Oct 6, 25$9.39Oct 8, 25$10.37Oct 10, 25$10.36Oct 14, 25$10.17Oct 16, 25$10.20Oct 21, 25$10.53Oct 23, 25$10.18Oct 27, 25$10.58Oct 29, 25$10.34Oct 31, 25$10.19Nov 4, 25$9.25Nov 6, 25$9.23Nov 10, 25$9.03Nov 12, 25$10.67Nov 14, 25$10.20Nov 18, 25$10.32Nov 20, 25$10.10Nov 25, 25$10.97Nov 28, 25$10.69Dec 2, 25$9.89Dec 4, 25$11.87Dec 8, 25$10.28Dec 10, 25$10.06Dec 12, 25$10.04Dec 16, 25$10.09Dec 18, 25$9.57Dec 22, 25$10.35Dec 24, 25$10.37Dec 29, 25$10.13Jan 2, 26$10.45Jan 6, 26$9.60Jan 8, 26$9.32Jan 12, 26$9.16Jan 14, 26$9.83Jan 16, 26$9.83Jan 21, 26$9.98Jan 23, 26$9.91Jan 27, 26$9.99Jan 29, 26$9.38Feb 2, 26$9.99Feb 4, 26$9.34Feb 9, 26$10.30Feb 11, 26$10.25Feb 13, 26$9.84Feb 18, 26$9.95Feb 20, 26$10.06Feb 24, 26$10.23Feb 26, 26$10.13Mar 2, 26$9.99Mar 4, 26$10.18Mar 6, 26$9.86Mar 10, 26$10.50Mar 12, 26$9.41Mar 17, 26$9.83Mar 19, 26$9.71Mar 23, 26$9.51Mar 25, 26$9.74Mar 27, 26$9.37Mar 31, 26$9.84Apr 2, 26$10.35Apr 7, 26$10.25Apr 9, 26$10.66Apr 13, 26$10.87Apr 15, 26$11.00Apr 17, 26$11.17Apr 22, 26$11.26Apr 24, 26$11.35Apr 28, 26$11.59Apr 30, 26$10.99May 4, 26$11.14May 6, 26$11.51May 8, 26$11.37May 12, 26$11.39May 14, 26$11.17May 18, 26$10.62May 20, 26$11.22May 22, 26$11.62May 28, 26$11.45Jun 1, 26$11.14Jun 3, 26$10.21Jun 5, 26$9.79Jun 9, 26$9.16Jun 11, 26$9.06Jun 15, 26$9.43Jun 17, 26$9.52Jun 22, 26$9.78Jun 24, 26$10.02Jun 26, 26$9.52Jul 2, 26$9.95
$5.0952-week range$11.87
Loading valuation history…

Fundamentals

Key fundamentals

$1.5B

Market cap

-69.0%

Revenue growth (YoY)

100.0%

Gross margin

-$201.3M

Free cash flow (USD)

-$453.5M

Net debt

Net cash position

12.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2018 → 2025

FY 2018$3.8MFY 2019$18.4MFY 2020$31.3MFY 2021$34.8MFY 2022$172.8MFY 2023$54.0MFY 2024$155.8MFY 2025$48.3M
$3.8M$48.3M

Free cash flow by year

2018 → 2025

FY 2018$20.2MFY 2019$68.7MFY 2020$-93.1MFY 2021$-87.4MFY 2022$93.9MFY 2023$-12.7MFY 2024$-174.5MFY 2025$-176.0M
$20.2M-$176M

Gross margin by year

2021 → 2025

FY 2021-151.9%FY 202238.2%FY 2023-119.8%FY 2024100.0%FY 2025100.0%
-151.9%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Jun 18, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Annual reportAnnual Report FiledJun 18, 2026Filing
  • 6-K filingStock Option PlanJun 2, 2026Filing
  • 6-K filingCorporate PresentationJun 1, 2026Filing
  • Quarterly reportQuarterly Report FiledMay 12, 2026Filing
  • 6-K filingUpcoming Oral PresentationsApr 21, 2026Filing
  • 6-K filingPress ReleaseApr 17, 2026Filing

Questions

Frequently asked questions

What is Immatics N.V.'s market cap?

Immatics N.V. (IMTX) has a market capitalization of $1.5B.

What is IMTX's P/E ratio?

A meaningful P/E ratio is not available for IMTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying IMTX stock?

SEC Form 4 filings show no open-market insider buys at Immatics N.V. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

INBX

Inhibrx Biosciences, Inc.

$1.5B

ARDX

Ardelyx, Inc.

$1.5B

NRIX

Nurix Therapeutics, Inc.

$1.5B

MAZE

Maze Therapeutics, Inc.

$1.5B

TSHA

Taysha Gene Therapies, Inc.

$1.5B

VRDN

Viridian Therapeutics, Inc.

$1.6B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.